- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-594/18 RENV: Order of the General Court of 15 November 2024 – Pharma Mar v Commission (Public health – Medicinal products for human use – Regulation (EC) No 726/2004 – Decision refusing marketing authorisation for Aplidin – plitidepsin, a medicinal product for human use – Withdrawal of the contested decision – No need to adjudicate)
ECLI:EU:UNKNOWN:62018TB0594
62018TB0594
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2025/568
3.2.2025
(Case T-594/18 RENV)
(Public health - Medicinal products for human use - Regulation (EC) No 726/2004 - Decision refusing marketing authorisation for Aplidin - plitidepsin, a medicinal product for human use - Withdrawal of the contested decision - No need to adjudicate)
(C/2025/568)
Language of the case: English
Parties
Applicant: Pharma Mar, SA (Colmenar Viejo, Spain) (represented by: M. Merola and V. Salvatore, lawyers)
Defendant: European Commission (represented by: E. Mathieu, L. Haasbeek and A. Spina, acting as Agents)
Interveners in support of the defendant: Federal Republic of Germany (represented by: J. Möller and P.-L. Krüger, acting as Agents), Republic of Estonia (represented by: M. Kriisa, acting as Agent), Kingdom of the Netherlands (represented by: M. Bulterman and C. Schillemans, acting as Agents), European Medicines Agency (represented by: S. Drosos, H. Kerr and G. Gavriilidou, acting as Agents)
Re:
By its action under Article 263 TFEU, the applicant seeks the annulment of Commission Implementing Decision C(2018) 4831 final of 17 July 2018 refusing marketing authorisation for ‘Aplidin – plitidepsin’, a medicinal product for human use, under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended by Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October 2012 (OJ 2012 L 316, p. 38).
Operative part of the order
1.There is no longer any need to adjudicate on the action.
2.The European Commission shall bear its own costs and pay those incurred by Pharma Mar, SA in the proceedings before the General Court and before the Court of Justice.
3.The Federal Republic of Germany, the Republic of Estonia, the Kingdom of the Netherlands and the European Medicines Agency (EMA) shall bear their own costs in relation to the appeal proceedings before the Court of Justice in Cases C-6/21 P and C-16/21 P and to the proceedings following the referral back to the General Court in Case T-594/18 RENV.
*
Language of the case: English.
ELI: http://data.europa.eu/eli/C/2025/568/oj
ISSN 1977-091X (electronic edition)
—
* * *
*1 Language of the case: English.